Global Influenza Diagnostics Market

Influenza Diagnostics Market Size, Share, Growth Analysis, By Test Type(Traditional Diagnostic Test, Molecular Diagnostic Assay), By End-User(Hospital, Laboratories, Other End Users), By Region - Industry Forecast 2024-2031


Report ID: SQSG35G2011 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 62 | Figures: 75

Influenza Diagnostics Market Competitive Landscape

The Influenza Diagnostics market is undergoing greater regulatory scrutiny. Presently, companies spend considerable resources on clinical trials and submissions to meet regulatory requirements for diagnosing new tests. This may impose substantial pressure on the cost of developing novel influenza diagnostics technologies. Therefore, governments across the globe are developing regulations to manage the development and control the cost of testing. These regulations can significantly impact the things for the market and products will be affected for the development and adoption perspective.

Influenza Diagnostics Market Top Player’s Company Profiles

  • Thermo Fisher Scientific, Inc.
  • Roche Diagnostics
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Quidel Corporation
  • DiaSorin S.p.A.
  • bioMérieux SA
  • Meridian Bioscience, Inc.
  • Luminex Corporation
  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Cepheid Inc.
  • Sekisui Diagnostics LLC
  • GenMark Diagnostics, Inc.
  • Quanterix Corporation
  • Alere Inc.
  • Merck KGaA
  • Hologic, Inc.
  • Scienion AG
  • Enzo Biochem, Inc.

Influenza Diagnostics Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Influenza Diagnostics Market size was valued at USD 1.07 billion in 2019 and is poised to grow from USD 1.1 billion in 2023 to USD 1.46 billion by 2031, growing at a CAGR of 3.5% in the forecast period (2024-2031).

The Influenza Diagnostics market is undergoing greater regulatory scrutiny. Presently, companies spend considerable resources on clinical trials and submissions to meet regulatory requirements for diagnosing new tests. This may impose substantial pressure on the cost of developing novel influenza diagnostics technologies. Therefore, governments across the globe are developing regulations to manage the development and control the cost of testing. These regulations can significantly impact the things for the market and products will be affected for the development and adoption perspective. 'Thermo Fisher Scientific, Inc.', 'Roche Diagnostics', 'Abbott Laboratories', 'Becton, Dickinson and Company', 'Quidel Corporation', 'DiaSorin S.p.A.', 'bioMérieux SA', 'Meridian Bioscience, Inc.', 'Luminex Corporation', 'Hologic, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Cepheid Inc.', 'Sekisui Diagnostics LLC', 'GenMark Diagnostics, Inc.', 'Quanterix Corporation', 'Alere Inc.', 'Merck KGaA', 'Hologic, Inc.', 'Scienion AG', 'Enzo Biochem, Inc.'

The rising global prevalence of influenza has surged the R&D activities for the accurate detection and diagnosis. Although the major concentration of research activities is targeted towards the development of a rapid and precise diagnosis of the influenza viruses, it will drive market growth as well. In addition to this, the rising incidences of government initiatives against the outbreak of influenza, technological advancements, and the increasing incidences of cardiovascular diseases and diabetes will provide a further push to market growth. 

Increasing in the Reported Cases of Influenza: The global influenza diagnostics market is expected to experience growth due to the increased occurrence of influenza. According to the centers for disease control and prevention on average about 12,000- 79,000 people die of Influenza each year in the United States. The market is also expected to grow during the forecast period because of the increasing awareness of the importance of early detection and prevention of diseases such as influenza. 

North America is dominating the Influenza Diagnostics market with the largest market share. The North American region dominated the diagnostic market in 2023 which was mainly due to the government’s support for high-quality healthcare, increase in focus of influenza outbreak, and the high buying power. The U.S. was the largest revenue contributor to the North American market in 2023. This is mainly because the U.S. market is expected to grow due to the well-established healthcare infrastructure and increase in programs for influenza diagnostics. These factors are increasing the growth of the influenza diagnostics market in the North America region.   

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Influenza Diagnostics Market

Report ID: SQSG35G2011

$5,300
BUY NOW GET FREE SAMPLE